Navigation Links
Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C

clinical investigations of small numbers of patients will not be reflected in clinical trials involving larger numbers of patients, that unexpected and adverse outcomes in other ongoing clinical and nonclinical studies will occur, that the FDA or other regulatory authorities will require additional and unanticipated studies or clinical trial outcomes before granting regulatory approval, and other risks listed under Risk Factors in Vertex's Form 10-K filed with the Securities and Exchange Commission on March 1, 2007. Vertex disclaims any obligation to update the information contained in this press release as new data become available.

(VRTX-G)

Contact

Vertex Pharmaceuticals Incorporated
Lynne H. Brum, 617-444-6614
VP, Strategic Communications
or
Michael Partridge, 617-444-6108
Director, Corporate Communications
or
Patricia Farrell, 617-444-6533
Director, Public Relations
or
Lora Pike, 617-444-6755
Manager, Investor Relations
or
Zachry Barber, 617-444-6470
Senior Media Relations Specialist
or
Tibotec Pharmaceuticals, Ltd.
Karen Manson, Mobile: +32 479 894 799
VP Communications and Public Affairs
Office: +32 15 461 019


'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
4. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
5. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
6. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
7. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
8. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
9. Avalon Pharmaceuticals Announces Positive Interim Results For AVN944 Phase I Trial
10. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
11. Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death
Post Your Comments:
(Date:4/24/2015)... -- Perrigo Company plc ("Perrigo" or the "Company") (NYSE: PRGO, ... from Mylan NV ("Mylan") (NASDAQ: MYL ) to ... $60.00 per share in cash and 2.2 Mylan ordinary ... The Board previously concluded that Mylan,s unsolicited ... and its future growth prospects and was not in ...
(Date:4/24/2015)... -- Bayer Corporation hosted its annual "Take Your Child to Work ... headquarters.  This is Bayer,s second "Take Your Child To Work ... campus, and Thursday,s event welcomed 230 children ready to see ... Fortunately, for the kids, this was not just another ... "Science For A Better Life," Bayer made sure that "Take ...
(Date:4/24/2015)... , April 24, 2015  IGI Laboratories, Inc. (NYSE ... based specialty generic pharmaceutical company, announced the Company will ... Tuesday, April 28, 2015 to discuss the 1st quarter ... listen to the call by dialing 1-888-346-3479. International participants ... should ask to be joined into the IGI Laboratories, ...
Breaking Medicine Technology:Perrigo Rejects Mylan Unsolicited Offer 2Perrigo Rejects Mylan Unsolicited Offer 3Perrigo Rejects Mylan Unsolicited Offer 4Bayer Hosts "Take Your Child to Work Day" 2Bayer Hosts "Take Your Child to Work Day" 3Bayer Hosts "Take Your Child to Work Day" 4
... Calif., March 31, 2011 NewCardio, Inc., (OTC Bulletin ... developer, announced today that the Company has been invited ... performance study at an upcoming conference entitled "Cardiovascular Safety ... Food and Drug Administration (FDA), the Cardiac Safety Research ...
... 31, 2011 The U.S. Department of Energy has ... field of medical technology and innovation for commercializing the ... agency, Dilon and similar entrepreneurs, "build the new industries ... our toughest global challenges." The Dilon 6800® ...
Cached Medicine Technology:NewCardio Invited to Present Latest QTinno Performance Improvements at FDA-Sponsored Conference on Cardiovascular Safety in Drug Development 2NewCardio Invited to Present Latest QTinno Performance Improvements at FDA-Sponsored Conference on Cardiovascular Safety in Drug Development 3NewCardio Invited to Present Latest QTinno Performance Improvements at FDA-Sponsored Conference on Cardiovascular Safety in Drug Development 4NewCardio Invited to Present Latest QTinno Performance Improvements at FDA-Sponsored Conference on Cardiovascular Safety in Drug Development 5NewCardio Invited to Present Latest QTinno Performance Improvements at FDA-Sponsored Conference on Cardiovascular Safety in Drug Development 6U.S. Department of Energy Hails Dilon Diagnostics as a Medical Technology Pioneer and Top National Innovator 2
(Date:4/27/2015)... (PRWEB) April 27, 2015 Winscribe ... to their suite of mobile speech productivity technology, ... iOS tablets and smartphones. , Winscribe ... Operating System since 2005. With the latest ... fourth generation mobile application interface in the last ...
(Date:4/27/2015)... Pure n Natural Systems, Inc. is pleased to ... at http://www.purennatural.com/ . The new website includes ... featured and sale items, as well as the official ... n Natural Systems’ website is designed to give customers ... neatly organized and provides plenty of useful information to ...
(Date:4/27/2015)... Aliso Viejo, CA (PRWEB) April 27, 2015 ... directly on top of footage with ProTelestrator from Pixel Film ... to draw a freehand sketch over a moving or still ... broadcasts to diagram and analyze sports plays or incoming weather ... "Animate Mode" checkbox and then adjust the frame slider to ...
(Date:4/27/2015)... Cambia Health Solutions is pleased to ... as Operating Partner within its Direct Health Solutions ... building companies that change the way people experience the ... be responsible for accelerating Cambia’s investments, which are focused ... economically sustainable and person-focused, while looking for new strategic ...
(Date:4/27/2015)... April 27, 2015 Doping has been ... Armstrong and Alex Rodriguez continue to capture the public’s ... a new frontier in performance enhancement along with new ... TV , accomplished neuroscientist Anjan Chatterjee of ... the ethics and dangers of these enhancements in sports. ...
Breaking Medicine News(10 mins):Health News:Winscribe Professional Dictation for Smartphones Evolves as Microsoft’s Mobile OS Grows 2Health News:Winscribe Professional Dictation for Smartphones Evolves as Microsoft’s Mobile OS Grows 3Health News:Winscribe Professional Dictation for Smartphones Evolves as Microsoft’s Mobile OS Grows 4Health News:Pure n Natural Systems, Inc. Launches New Website Design 2Health News:Pure n Natural Systems, Inc. Launches New Website Design 3Health News:Pixel Film Studios releases ProTelestrator for Final Cut Pro X. 2Health News:Cambia Welcomes Ben Albert as Operating Partner 2Health News:Cambia Welcomes Ben Albert as Operating Partner 3Health News:The Brain, Smart Drugs, and Sports on SCI TV with Anjan Chatterjee 2Health News:The Brain, Smart Drugs, and Sports on SCI TV with Anjan Chatterjee 3
... Study says surgical advances may explain away the link ... News) -- Cataract surgery doesn,t hasten vision loss in ... conclusion of a new study that challenges the findings ... between cataract surgery and accelerated AMD progression. , AMD ...
... mouse model of human leukemia has provided critical insight into ... myeloid leukemia stem cells. The study, published by Cell Press ... Stem Cell , is likely to have a profound impact ... stem cells. , Leukemia stem cells (LSCs) were initially described ...
... Patient Advocate Foundation (NPAF) -- a national, non-profit organization ... patient access to health care through public policy reform ... Congress for passing and President Obama for signing the ... extend health coverage to four million uninsured American children. ...
... disease, A Su Salud revealed high incidence of diabetes, ... $55 million in free and low cost medical services ... -- CVS/pharmacy, the nation,s leading retail ... Salud" (To Your Health) health fairs, providing free health ...
... Montreal, Canada February 05, 2009 A ... who have received kidney transplants and compares them ... a significantly higher prevalence of psychiatric conditions (depression, ... adolescents who had undergone a transplant. The study ...
... recent survey of in-house,physician recruiters across the country ... on hospital systems throughout the United States, and,recruiting ... the lack,of physicians to fill key provider roles. ... from their most recent recruitment,and retention survey of ...
Cached Medicine News:Health News:Cataract Surgery Doesn't Worsen AMD 2Health News:Leukemia stem cells have more in common with embryonic stem cells than adult stem cells 2Health News:National Patient Advocate Foundation Applauds Congress' and President Obama's Decision to Extend Health Coverage to Four Million Uninsured Children 2Health News:CVS/pharmacy Launches 2009 'A Su Salud' Health Fairs Providing Free Health Screenings to the Community 2Health News:CVS/pharmacy Launches 2009 'A Su Salud' Health Fairs Providing Free Health Screenings to the Community 3Health News:Psychological impact found in adolescents with kidney transplants 2Health News:PracticeMatch: Healthcare Survey Defines Physician Recruitment Challenges 2
Full Handle Laseredge Slit Blade Knife, 3.0 mm angled bevel up. Blade tip dimension: 14.4 mm x 3.0 mm x 3.7 mm....
Full Handle Laseredge Slit Blade Knife, 2.85 mm slit. Blade tip dimension: 14.1 mm x 2.85 mm x 3.3 mm....
Full Handle Laseredge Slit Blade Knife, 2.65 mm angled double bevel. Blade tip dimension: N/A x 2.65 mm x N/A....
Full Handle Laseredge Slit Blade Knife, 2.65 mm angled bevel up. Blade tip dimension: 14.4 mm x 2.65 mm x 3.7 mm....
Medicine Products: